22,238 Shares in Fulgent Genetics, Inc. (NASDAQ:FLGT) Acquired by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) during the 4th quarter, Holdings Channel.com reports. The fund purchased 22,238 shares of the company’s stock, valued at approximately $411,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wealthspire Advisors LLC purchased a new position in shares of Fulgent Genetics in the 4th quarter valued at $186,000. TCW Group Inc. boosted its stake in Fulgent Genetics by 2.7% in the fourth quarter. TCW Group Inc. now owns 123,400 shares of the company’s stock valued at $2,279,000 after acquiring an additional 3,300 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Fulgent Genetics by 3.8% during the fourth quarter. Principal Financial Group Inc. now owns 97,926 shares of the company’s stock worth $1,809,000 after purchasing an additional 3,615 shares during the last quarter. Peapod Lane Capital LLC acquired a new stake in shares of Fulgent Genetics during the fourth quarter worth about $2,022,000. Finally, Empowered Funds LLC lifted its holdings in shares of Fulgent Genetics by 5.1% in the 4th quarter. Empowered Funds LLC now owns 95,011 shares of the company’s stock valued at $1,755,000 after purchasing an additional 4,609 shares during the last quarter. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Stock Performance

NASDAQ FLGT opened at $16.96 on Tuesday. The firm’s fifty day moving average is $16.82 and its two-hundred day moving average is $18.77. Fulgent Genetics, Inc. has a one year low of $14.57 and a one year high of $25.11. The firm has a market cap of $522.86 million, a PE ratio of -3.07 and a beta of 1.54.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Piper Sandler dropped their price target on Fulgent Genetics from $22.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. StockNews.com upgraded shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 5th.

Insider Buying and Selling

In related news, CFO Paul Kim purchased 100,000 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was acquired at an average price of $15.96 per share, for a total transaction of $1,596,000.00. Following the completion of the purchase, the chief financial officer now directly owns 348,282 shares of the company’s stock, valued at $5,558,580.72. This trade represents a 40.28 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 31.76% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.